Arctic Vision of Shanghai Completes $100 Million Series B Round

Arctic Vision, a Shanghai ophthalmology company, completed a Series B financing of over $100 million led by Loyal Valley Capital. The company has in-licensed greater China rights to three products, including a commercial-stage therapy for uveitic macular edema. In 2020, Arctic , which was incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China, completed a $32 million Series A funding. Arctic plans to use the latest proceeds for clinical development of its portfolio, plus building in-house R&D and increasing business development. More details.... Share this with colleagues: // //